Results from a Cross-Sectional Observational Study Examining Irritable Bowel Syndrome Patients Six Months After Finishing Their Participation in the ViIBS Trial
Nutrients · 2024
DOI: 10.3390/nu16223911 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Nutrients, 2024. Verfasst von Henning Sommermeyer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Calisia University, Nowy Swiat 4, 62-800 Kalisz, Poland. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Probiotics, Synbiotics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives. A recent clinical (ViIBS) trial investigating the effects of a balanced multi-strain synbiotic in irritable bowel syndrome (IBS) patients showed that twelve weeks of treatment resulted in significant improvements across all major IBS symptoms. The current observational study pursued three aims: investigate patients’ attitude towards the intake of pro- or synbiotics during the six months after finishing their trial participation, determine the severity of IBS symptoms, and assess IBS diagnosis scores.
Methods
During a single six-month follow-up examination, patients were asked about the intake of probiotics or synbiotics. For the study, former placebo-group patients who abstained from taking probiotics were compared with synbiotic-group patients who continued taking the tested synbiotic. IBS symptom severity was assessed with the IBS—Severity of Symptoms Scale and the IBS diagnosis score with the IBS questionnaire of the World Gastroenterology Organisation.
Results
The control group comprised 17 patients (out of 70 from the placebo group participating in the follow-up) and the treatment group 75 (out of 91 examined). IBS symptom severity was significantly lower in the treatment group (23.5 ± 33.1) than in the placebo group (232.6 ± 35.1). IBS diagnosis scores were 5.9 ± 2.5 and 21.2 ± 2.0 in the treatment and control group, respectively.
Conclusions
Measurement values for the treatment group indicate the absence of IBS. The results indicate that the prolonged administration of the balanced multi-strain synbiotic can potentially reduce IBS symptom severity and IBS diagnosis scores to levels indicating the absence of IBS, an observation to be followed up in a controlled clinical trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Sciences, Calisia University, Nowy Swiat 4, 62-800 Kalisz, Poland.
- Department of Hygiene and Epidemiology, Collegium Medicum, University of Zielona Góra, 28 Zyty St., 65-046 Zielona Góra, Poland.
ORCID-Profile: Henning Sommermeyer, Krzysztof Chmielowiec, Jacek Piątek
Zitieren
APA
Sommermeyer, H., Chmielowiec, K., Bernatek, M., Olszewski, P., Kopczynski, J., & Piątek, J. (2024). Results from a Cross-Sectional Observational Study Examining Irritable Bowel Syndrome Patients Six Months After Finishing Their Participation in the ViIBS Trial. Nutrients. https://doi.org/10.3390/nu16223911
Vancouver
Sommermeyer H, Chmielowiec K, Bernatek M, Olszewski P, Kopczynski J, Piątek J. Results from a Cross-Sectional Observational Study Examining Irritable Bowel Syndrome Patients Six Months After Finishing Their Participation in the ViIBS Trial. Nutrients. 2024. doi:10.3390/nu16223911
BibTeX
@article{Sommermeyer2024,
author = {Sommermeyer, Henning and Chmielowiec, Krzysztof and Bernatek, Malgorzata and Olszewski, Pawel and Kopczynski, Jaroslaw and Piątek, Jacek},
title = {Results from a Cross-Sectional Observational Study Examining Irritable Bowel Syndrome Patients Six Months After Finishing Their Participation in the ViIBS Trial},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16223911}
}
EUVIMED